US biotech industry welcomes Supreme Court ruling against Microsoft
This article was originally published in Clinica
Executive Summary
Tiny Canadian tech firm i4i became the fighter that felled the giant on 9 June when the US Supreme Court in an 8-0 ruling upheld a $290m judgment against Microsoft in a patent infringement case that has closely been watched by innovator drug makers, particularly small biotechs, as one of the most important patent lawsuits to go before the high court.